

**32<sup>nd</sup> Annual Cancer Progress Conference, May 4<sup>th</sup> – 6<sup>th</sup> 2021****May 4, 2021****9:00 – 9:15 am****Opening Remarks**

Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health

**9:15 – 10:00 am****Keynote: Engineering the Future: Next Gen Platforms in Oncology**

**Speaker:** Daniel S Chen, MD, PhD, Chief Medical Officer, IGM Biosciences

**10:15 – 11:30 am****Climbing the Highest Peak: Targeting PD-1/L1 Failures in Solid Tumors**

**Moderator:** Jeffrey M. Bockman, PhD, EVP, Oncology Practice Head, Cello Health BioConsulting and James T. Lee, PhD, Principal, Oncology Lead, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Neil Brewis, PhD, Chief Scientific Officer, F-star Therapeutics
- :Michael A Curran, PhD, Associate Professor, Dept. of Immunology  
Scientific Director, ORBIT Platform, The University of Texas MD Anderson Cancer Center,  
Department of Immunology, Division of Basic Sciences
- Kapil Dhingra, MD, Managing Member, KAPital Consulting LLC
- Thomas Schuetz, MD, PhD, CEO and Co-founder, Compass Therapeutics
- Emmett Schmidt, MD, PhD, Associate Vice President, Clinical Oncology & Lead, External  
Collaborations, Merck Research Laboratories

**11:45 am – 1:00 pm****Multifunctional Soluble Biologics: Binders, Binders Everywhere**

**Moderator:** James T. Lee, PhD, Principal, Oncology Lead, and Serom Lee, PhD, Consultant, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Philip Bland-Ward, PhD, Chief Development Officer, Crescendo Biologics Ltd
- Alicia Chung, PhD, Corporate Development, Amphivena Therapeutics Inc
- Eliot Forster, BSc, PhD, MBA, FRSA, Chief Executive Officer, F-star Therapeutics
- Valerie Odegard, PhD, CSO, Silverback Therapeutics
- Taylor H. Schreiber, MD, Ph.D, Chief Executive Officer Shattuck Labs, Inc

**1:00 - 1:30 pm****Break for Lunch**

**1:30 – 2:45 pm Tumor Agnostic Development**

**Moderator:** TBD

**Panelists:**

- Brian Leyland Jones, MB BS, PhD, CMO, National Foundation For Cancer Research
- Mark Pegram, MD, Professor of Medical Oncology, Stanford Comprehensive Cancer Institute, Stanford University

**3:00 – 4:15 pm Accelerated Development Paths**

**Moderator:** Brian Leyland Jones, MB BS, PhD, CMO, National Foundation For Cancer Research

**Panelists:**

- Professor Paul Workman, Chief Executive and President, [The Institute of Cancer Research](#), London
- Ralph E. Parchment, PhD, Managing Director, DCTD Program in Pharmacodynamic Biomarkers, NCI

**4:30 – 5:45 pm Endogenous Reprogramming: Anything One Can Do Ex Vivo, Can One Do In Vivo (and Do Better)?**

**Moderator:** Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Jacob Becraft, PhD, CEO, Co-founder, Strand Therapeutics
- Nicholas A. Boyle, PhD, MBA, CEO, Abintus Bio
- Mary Haak-Frendscho, PhD, President & CEO, Spotlight Therapeutics
- Stephan Matthias, MD PhD, Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Center
- Ulrik Nielsen, PhD, CEO, Tidal Therapeutics

**5:45 pm Day 1 Cancer Progress 2021 Conference Conclude**

**May 5, 2021**

**9:00 – 9:15 am**

**Opening Remarks: Review of Day 1**

Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting, previously Defined Health

**9:15- – 10:00 am**

**Keynote Address: Title TBD**

**Speaker:** Katy Rezvani, MD, PhD, Principal Investigator, Professor, Stem Cell Transplantation & Cellular Therapy Department, MD Anderson Cancer Center

**10:15- 11:30 am**

**Allogeneic Cell Therapy: Stocking the Shelf Part I (NKs, NKTs)**

**Moderator:** Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting, previously Defined Health

**Panelists**

- Jason B. Litten, MD, Chief Medical Officer, Artiva Biotherapeutics, Inc., Artiva Biotherapeutics
- Annemarie Moseley, MD PhD, CEO, Sandhill Therapeutics
- Kelly Page, Global Head of Cell Therapy Commercialization of Cell Therapy Commercialization, Takeda
- Alan Trounson, MSc, PhD, CEO and Executive Director Cartherics
- Kurt Gunter, MD, Chief Medical Officer,kuur

**11:45- 1:00 pm**

**Allogeneic Cell Therapy: Stocking the Shelf Part II (Traditional T-cells, Gamma-deltas)**

**Moderator:** Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Greg Block, PhD, SVP Corporate Development, Notch Therapeutics
- Rachel Haurwitz, PhD, Chief Executive Officer and Founder Caribou Biosciences, Inc.
- Sandy Hayes, Adicet/resTORbio
- Ajla Hrle, PhD, Director, Head of Strategic Alliances, Immatix Biotechnologies

**1:00 – 1:30 pm**

**Break for Lunch**

**1:30 – 2:45 pm**

**Cell Therapy in Solid Tumors: Freedom of the Open Road**

**Moderator:** Joel S. Sandler, PhD, Principal, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Sharon Benzeno, SVP, Drug Discovery, Adaptive Biotechnologies Corp.
- John Delyani, PhD VP, Corporate Development, Tminuty Therapeutics Inc
- Mythili Koneru, MD, PhD, Chief Medical Officer, Marker Therapeutics
- Peter Sandor, MD, MBA, Head of Oncology TA Marketing Strategy, Astellas
- Helen Tayton-Martin, PhD, MBA, Chief Business Officer, Adaptimmune **LLC**
- Paul Wotton, PhD, CEO, Obsidian Therapeutics, Inc.

**3:00- 4:15 pm**

**Validating New Platforms: Clinical Pain, Commercial Gain**

**Moderator:** Joel S. Sandler, PhD, Principal, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Robert Ang, MD, MBA, President & CEO, Vor Bio Pharm
- Debora Barton, MD, Chief Medical Officer, Carisma Therapeutics Inc.
- Lawrence Lamb, PhD, Scientific Co-Founder & Chief Scientific Officer, in8bio
- Jan ter Meulen, MD, PhD CSO, Obsidian Therapeutics, Inc.
- Dan Shoemaker, PhD, Chief Scientific Officer, Fate
- Gracell Biotechnologies, TBD

**4:30-5:45 pm**

**Counterpoint to Over-engineering: Bauhaus Minimalism in an Era of More Opulent T-cell Architecture**

**Moderator:** Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Keith Bahjat, Sr Director Science, Cell Therapy Center of Excellence, Astellas
- Frank Borriello, MD, PhD, Founder & Chief Executive Officer, Alloplex Biotherapeutics
- Sabine Chlosta, MD, Chief Medical Officer, Triumvera
- Kimberly Noonan, PhD, Founder, EVP & Chief Scientific Officer WindMIL
- Paul D. Rennert, President & Chief Scientific Officer, Aleta Biotherapeutics
- Immatix, TBD

**Day 2 Cancer Progress 2021 Conference Concludes**

**May 6, 2021**

**8:15 – 8:30 am**

**Opening Remarks: Review of Day 2**

**8:30 – 9:45 am**

**China Panel**

**Moderator:** James T. Lee, PhD, Principal, Oncology Lead, and Serom Lee, PhD, Consultant, Cello Health BioConsulting, previously Defined Health

**Panelists:**

**10:00- 11:15 am**

**Investing in the *Emerald City* of Oncology Innovation: Platforms & Modalities & Targets, Oh My!**

**Moderator:** Mark Simon, Partner and Co-Founder, Torreyia

**Panelists:**

- Margarita Chavez, JD, Managing Director, AbbVie Ventures (tentative)
- Kapil Dhingra, MD, Managing Member, KAPital Consulting LLC
- Maha Katabi, PhD, CFA , General Partner, Sofinnova Investments
- Carolyn Ng, Director, Vertex Ventures
- Anna Turetsky, Principal, Venture Investments, The Mark Foundation

**11:30 am - 12:45 pm**

**Heme Malignancies Transformed: An Idiosyncratic Comparison of Multiple Myeloma and AML**

**Moderator:** Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Kenneth C. Anderson, MD, Dana-Farber Cancer Institute
- Lee Greenberger, MD, PhD, SVP & CSO, Leukemia & Lymphoma Society
- Daniel A Pollyea, MD MS, Associate Professor of Medicine, Division of Hematology, University of Colorado School of Medicine

**12:45- 1:15 pm**

**Break for Lunch**

**1:30 - 2:45 pm**

**Let's Make a Deal in Oncology: What's Behind the Doors & Who Has the Keys?**

**Moderator:** Jeremy Goldberg, Operating Partner, Arsenal Capital Partners

**Panelists:**

- Christopher Mortko, Director and Oncology Search & Evaluation Lead, Merck & Co., Inc
- Peter Sandor, MD, MBA, Head of Oncology TA Marketing Strategy, Astellas

**3:00- 4:15 pm**

**Value Panel**

**Moderators:** Ed Saltzman, Executive Chairman, Cello Heath BioConsulting

**Panelists:**

- Ron Akehurst, Chairman, BresMed
- Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Michael Kolodziej, MD, VP and CIO, ADVI Health
- Leonard Saltz, MD, Executive Director for Clinical Value & Sustainability; Head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center

**4:30 – 5:30pm**

**Battle of the Modalities- The sequel**

- Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health
- James T. Lee, PhD, Principal, Oncology Lead, and Serom Lee, PhD, Consultant, Cello Health BioConsulting, previously Defined Health
- Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting, previously Defined Health
- Joel S. Sandler, PhD, Principal, Cello Health BioConsulting, previously Defined Health

**Cancer Progress 2021 Conference Concludes**